Portable ultrasound vendor SonoSite topped the $10 million mark in revenues in its first year since being spun off by ATL. Not surprisingly, the bulk of those revenues came in the fourth quarter (end-December), following launch of the Bothell, WA-based
Portable ultrasound vendor SonoSite topped the $10 million mark in revenues in its first year since being spun off by ATL. Not surprisingly, the bulk of those revenues came in the fourth quarter (end-December), following launch of the Bothell, WA-based companys first two commercial product platforms, the SonoSite 180 hand-held ultrasound system and the SonoHeart hand-held echocardiography system (SCAN 9/29/99 and 1/12/00). SonoSite began shipping SonoHeart this month.
Despite revenues of $9.4 million for the fourth quarter and $10.1 million for the year, SonoSite still reported hefty losses at years end: Losses for the year were $21.6 million, compared to $13 million for 1998. This was due in part to increases in operating expenses related to product and personnel ramp-up in support of the companys new product lines. Fourth-quarter losses reflect the companys new revenue streams, however; losses for the quarter were $3.2 million, compared to losses of $4.7 million for the fourth quarter of 1998.
Philips Launches Flash 5100 Point-of-Care Ultrasound System
June 17th 2025Offering a combination of intuitive touchscreen controls and enhanced image clarity, the portable Flash 5100 POC ultrasound platform reportedly facilitates confident and rapid assessment in emergency radiology and critical care settings.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.